Advertisement

Effectiveness and safety of high and low dose NOACs in patients with atrial fibrillation

  • Author Footnotes
    1 Both authors equally contributed
    Irene Marzona
    Footnotes
    1 Both authors equally contributed
    Affiliations
    Department of Cardiovascular Medicine, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy
    Search for articles by this author
  • Author Footnotes
    1 Both authors equally contributed
    Marco Proietti
    Footnotes
    1 Both authors equally contributed
    Affiliations
    Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy

    Geriatric Unit, Fondazione IRCCS Ca’ Granda, Ospedale Maggiore Policlinico, Milan, Italy

    Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart and Chest Hospital, Liverpool, UK
    Search for articles by this author
  • Pierluca Colacioppo
    Affiliations
    Department of Cardiovascular Medicine, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy
    Search for articles by this author
  • Andreana Foresta
    Affiliations
    Department of Cardiovascular Medicine, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy
    Search for articles by this author
  • Marta Baviera
    Correspondence
    Corresponding author at: Laboratory of Cardiovascular Prevention, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Via Mario Negri 2, 20156, Milan, Italy
    Affiliations
    Department of Cardiovascular Medicine, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy
    Search for articles by this author
  • Author Footnotes
    1 Both authors equally contributed
Published:February 18, 2021DOI:https://doi.org/10.1016/j.ejim.2021.01.031

      Highlights

      • NOACs effectiveness/safety has been described according to dose in a large AF cohort.
      • NOACs high dose decreased the risk of all-cause death.
      • NOACs high and low dose decreased the risk of intracranial bleeding.
      • NOACs low dose increased the rate of major bleeding.
      • Evaluation of the patients’ characteristic is pivotal choosing the proper NOACs dose.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Internal Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Proietti M.
        • Lane D.A.
        • Boriani G.
        • Lip G.Y.H.
        Stroke prevention, evaluation of bleeding risk, and anticoagulant treatment management in atrial fibrillation contemporary international guidelines.
        Can J Cardiol. 2019; 35: 619-633https://doi.org/10.1016/j.cjca.2019.02.009
        • Boriani G.
        • Proietti M.
        • Laroche C.
        • Fauchier L.
        • Marin F.
        • Nabauer M
        • et al.
        Contemporary stroke prevention strategies in 11 096 European patients with atrial fibrillation: a report from the EURObservational research programme on atrial fibrillation (EORP-AF) long-term general registry.
        Europace. 2018; 20: 747-757https://doi.org/10.1093/europace/eux301
        • Ortiz M.R.
        • Muñiz J.
        • Míguez P.R.
        • Roldán I.
        • Marín F.
        • Esteve-Pastor M.A.
        • et al.
        Inappropriate doses of direct oral anticoagulants in real-world clinical practice: prevalence and associated factors. A subanalysis of the FANTASIIA registry.
        Europace. 2018; 20: 1577-1583https://doi.org/10.1093/europace/eux316
        • Arbel R.
        • Sergienko R.
        • Hammerman A.
        • Greenberg-Dotan S.
        • Batat E.
        • Avnery O.
        • et al.
        Effectiveness and safety of off-label dose-reduced direct oral anticoagulants in atrial fibrillation.
        Am J Med. 2019; 132: 847-855https://doi.org/10.1016/j.amjmed.2019.01.025
        • Cho M.S.
        • Yun J.E.
        • Park J.J.
        • Kim Y.J.
        • Lee J.
        • Kim H.
        • et al.
        Pattern and impact of off-label underdosing of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation who are indicated for standard dosing.
        Am J Cardiol. 2020; 125: 1332-1338https://doi.org/10.1016/j.amjcard.2020.01.044
        • Steinberg B.A.
        • Shrader P.
        • Pieper K.
        • Thomas L.
        • Allen L.A.
        • Ansell J.
        • et al.
        Frequency and outcomes of reduced dose non-vitamin K antagonist anticoagulants: results from ORBIT-AF II (The outcomes registry for better informed treatment of atrial fibrillation II).
        J Am Heart Assoc. 2018; 7https://doi.org/10.1161/JAHA.117.007633
        • Steffel J.
        • Verhamme P.
        • Potpara T.S.
        • Albaladejo P.
        • Antz M.
        • Desteghe L.
        • et al.
        The 2018 European heart rhythm association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation.
        Eur Heart J. 2018; 39: 1330-1393https://doi.org/10.1093/eurheartj/ehy136
        • Nielsen P.B.
        • Skjøth F.
        • Søgaard M.
        • Kjældgaard J.N.
        • Lip G.Y.H.
        • Larsen T.B.
        Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.
        BMJ. 2017; 356: j510https://doi.org/10.1136/bmj.j510
        • Wang K.-L.
        • Lopes R.D.
        • Patel M.R.
        • Büller H.R.
        • Tan D.S.-Y.
        • Chiang C.-E.
        • et al.
        Efficacy and safety of reduced-dose non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: a meta-analysis of randomized controlled trials.
        Eur Heart J. 2019; 40: 1492-1500https://doi.org/10.1093/eurheartj/ehy802
        • Rivera-Caravaca J.M.
        • Roldán V.
        • Esteve-Pastor M.A.
        • Valdés M.
        • Vicente V.
        • Lip G.Y.H.
        • et al.
        Cessation of oral anticoagulation is an important risk factor for stroke and mortality in atrial fibrillation patients.
        Thromb Haemost. 2017; 117https://doi.org/10.1160/TH16-12-0961
        • Boriani G.
        • Proietti M.
        • Laroche C.
        • Fauchier L.
        • Marin F.
        • Nabauer M.
        • et al.
        Association between antithrombotic treatment and outcomes at 1-year follow-up in patients with atrial fibrillation: the EORP-AF general long-term registry.
        Europace. 2019; 21: 1013-1022https://doi.org/10.1093/europace/euz032
        • Cowan J.C.
        • Wu J.
        • Hall M.
        • Orlowski A.
        • West R.M.
        • Gale C.P.
        A 10 year study of hospitalized atrial fibrillation-related stroke in England and its association with uptake of oral anticoagulation.
        Eur Heart J. 2018; 39: 2975-2983https://doi.org/10.1093/eurheartj/ehy411
        • Dai H.
        • Zhang Q.
        • Much A.A.
        • Maor E.
        • Segev A.
        • Beinart R.
        • et al.
        Global, regional, and national prevalence, incidence, mortality, and risk factors for atrial fibrillation, 1990–2017: results from the global burden of disease study 2017.
        Eur Hear J - Qual Care Clin Outcomes. 2020; https://doi.org/10.1093/ehjqcco/qcaa061
        • Gómez-Outes A.
        • Lagunar-Ruíz J.
        • Terleira-Fernández A.I.
        • Calvo-Rojas G.
        • Suárez-Gea M.L.
        • Vargas-Castrillón E.
        Causes of death in anticoagulated patients with atrial fibrillation.
        J Am Coll Cardiol. 2016; 68: 2508-2521https://doi.org/10.1016/j.jacc.2016.09.944
        • Ruff C.T.
        • Giugliano R.P.
        • Braunwald E.
        • Hoffman E.B.
        • Deenadayalu N.
        • Ezekowitz M.D.
        • et al.
        Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials.
        Lancet. 2014; 383: 955-962https://doi.org/10.1016/S0140-6736(13)62343-0

      Linked Article